T. Rowe Price Associates’s Immunomedics Inc IMMU Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q4 | – | Sell |
-1,337,049
| Closed | -$114M | – | 2767 |
|
|
2020
Q3 | $114M | Sell |
1,337,049
-5,542,557
| -81% | -$280M | 0.01% | 615 |
|
|
2020
Q2 | $244M | Buy |
6,879,606
+1,950,783
| +40% | +$57M | 0.03% | 437 |
|
|
2020
Q1 | $66.4M | Sell |
4,928,823
-899,168
| -15% | -$15.1M | 0.01% | 697 |
|
|
2019
Q4 | $123M | Sell |
5,827,991
-77,288
| -1% | -$1.36M | 0.02% | 600 |
|
|
2019
Q3 | $78.3M | Sell |
5,905,279
-245,585
| -4% | -$3.61M | 0.01% | 709 |
|
|
2019
Q2 | $85.3M | Sell |
6,150,864
-2,959,466
| -32% | -$44.5M | 0.01% | 696 |
|
|
2019
Q1 | $175M | Sell |
9,110,330
-3,704,693
| -29% | -$59.7M | 0.03% | 501 |
|
|
2018
Q4 | $183M | Buy |
12,815,023
+226,388
| +2% | +$4.49M | 0.03% | 457 |
|
|
2018
Q3 | $262M | Buy |
12,588,635
+3,818,816
| +44% | +$90.5M | 0.04% | 414 |
|
|
2018
Q2 | $208M | Buy |
8,769,819
+1,790,358
| +26% | +$36M | 0.03% | 474 |
|
|
2018
Q1 | $102M | Buy |
6,979,461
+351,799
| +5% | +$5.75M | 0.02% | 644 |
|
|
2017
Q4 | $107M | Buy |
6,627,662
+251,530
| +4% | +$2.97M | 0.02% | 620 |
|
|
2017
Q3 | $89.1M | Buy |
6,376,132
+408,370
| +7% | +$4.07M | 0.02% | 657 |
|
|
2017
Q2 | $52.7M | Buy |
5,967,762
+1,271,920
| +27% | +$8.93M | 0.01% | 798 |
|
|
2017
Q1 | $30.4M | Buy |
4,695,842
+4,570,042
| +3,633% | +$23.2M | 0.01% | 989 |
|
|
2016
Q4 | $462K | Buy |
125,800
+12,700
| +11% | +$37.6K | ﹤0.01% | 2080 |
|
|
2016
Q3 | $368K | Buy |
113,100
+80,000
| +242% | +$224K | ﹤0.01% | 2135 |
|
|
2016
Q2 | $77K | Hold |
33,100
| – | – | ﹤0.01% | 2455 |
|
|
2016
Q1 | $83K | Hold |
33,100
| – | – | ﹤0.01% | 2433 |
|
|
2015
Q4 | $102K | Buy |
33,100
+300
| +0.9% | +$837 | ﹤0.01% | 2420 |
|
|
2015
Q3 | $56K | Hold |
32,800
| – | – | ﹤0.01% | 2464 |
|
|
2015
Q2 | $133K | Hold |
32,800
| – | – | ﹤0.01% | 2425 |
|
|
2015
Q1 | $126K | Hold |
32,800
| – | – | ﹤0.01% | 2438 |
|
|
2014
Q4 | $157K | Sell |
32,800
-10,000
| -23% | -$39.5K | ﹤0.01% | 2406 |
|
|
2014
Q3 | $159K | Hold |
42,800
| – | – | ﹤0.01% | 2395 |
|
|
2014
Q2 | $156K | Buy |
42,800
+13,000
| +44% | +$47.7K | ﹤0.01% | 2410 |
|
|
2014
Q1 | $125K | Hold |
29,800
| – | – | ﹤0.01% | 2408 |
|
|
2013
Q4 | $137K | Hold |
29,800
| – | – | ﹤0.01% | 2378 |
|
|
2013
Q3 | $184K | Hold |
29,800
| – | – | ﹤0.01% | 2288 |
|
|
2013
Q2 | $162K | Buy |
+29,800
| New | +$97.9K | ﹤0.01% | 2252 |
|
T. Rowe Price Associates's IMMU Position: Q4 2020 in Review
T. Rowe Price Associates sold out of Immunomedics Inc (IMMU) in Q4 2020, closing a stake of 1,337,049 shares — an estimated $114M sold.
T. Rowe Price Associates first reported a position in IMMU in Q2 2013 and held it in 30 quarters. The position peaked at $262M in Q3 2018. 0 funds tracked by Wall St. Rank hold IMMU as of Q4 2020.
- T. Rowe Price Associates reported no remaining Immunomedics Inc position as of Q4 2020 after selling out during the quarter.
- T. Rowe Price Associates sold 1,337,049 Immunomedics Inc shares in Q4 2020, an estimated $114M.
- T. Rowe Price Associates first reported a position in Immunomedics Inc in Q2 2013 and held it in 30 quarters.
- T. Rowe Price Associates's Immunomedics Inc position peaked at $262M in Q3 2018.
- 0 funds tracked by Wall St. Rank held Immunomedics Inc as of Q4 2020.
Based on T. Rowe Price Associates's 13F filing for Q4 2020, filed 16 Feb 2021.